Protara Therapeutics, Inc. (TARA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
19/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseTARA / S&P -26.68% / 15.20% |
LoseTARA / S&P TARA unavailable / 15.00% |
LoseTARA / S&P -13.38% / 50.40% |
| 2026-Q11/3 |
WinTARA / S&P -2.25% / -4.33% |
LoseTARA / S&P TARA unavailable / 11.30% |
LoseTARA / S&P -19.16% / 27.70% |
| 2025-Q41/3 |
WinTARA / S&P 22.53% / 2.65% |
LoseTARA / S&P TARA unavailable / 9.00% |
LoseTARA / S&P -43.40% / 13.40% |
| 2025-Q31/3 |
WinTARA / S&P 43.56% / 8.12% |
LoseTARA / S&P TARA unavailable / 4.61% |
LoseTARA / S&P -51.06% / 13.45% |
| 2025-Q20/3 |
LoseTARA / S&P -28.87% / 10.94% |
LoseTARA / S&P TARA unavailable / 4.83% |
LoseTARA / S&P -50.78% / 10.63% |
| 2025-Q10/3 |
LoseTARA / S&P -19.32% / -4.27% |
LoseTARA / S&P TARA unavailable / 4.98% |
LoseTARA / S&P -55.35% / 10.57% |
| 2024-Q41/3 |
WinTARA / S&P 188.52% / 2.41% |
LoseTARA / S&P TARA unavailable / 5.25% |
LoseTARA / S&P -34.17% / 6.15% |
| 2024-Q30/3 |
LoseTARA / S&P -12.02% / 5.89% |
LoseTARA / S&P TARA unavailable / 5.89% |
LoseTARA / S&P -54.00% / 6.11% |
| 2024-Q20/3 |
LoseTARA / S&P -48.13% / 4.28% |
LoseTARA / S&P TARA unavailable / 5.38% |
LoseTARA / S&P -46.30% / 5.12% |
| 2024-Q11/3 |
WinTARA / S&P 113.87% / 10.56% |
LoseTARA / S&P TARA unavailable / 5.71% |
LoseTARA / S&P -34.39% / 5.59% |
| 2023-Q41/3 |
WinTARA / S&P 12.28% / 11.69% |
LoseTARA / S&P TARA unavailable / 6.81% |
LoseTARA / S&P -39.08% / 7.78% |
| 2023-Q31/3 |
LoseTARA / S&P -30.13% / -3.27% |
LoseTARA / S&P TARA unavailable / 7.52% |
WinTARA / S&P 85.20% / -5.03% |
| 2023-Q21/3 |
LoseTARA / S&P -23.64% / 8.74% |
LoseTARA / S&P TARA unavailable / 9.50% |
WinTARA / S&P 65.46% / -8.57% |
| 2023-Q12/3 |
WinTARA / S&P 16.79% / 7.50% |
LoseTARA / S&P TARA unavailable / 10.77% |
WinTARA / S&P 43.58% / -15.69% |
| 2022-Q40/3 |
LoseTARA / S&P -9.46% / 7.56% |
LoseTARA / S&P TARA unavailable / 11.88% |
LoseTARA / S&P TARA unavailable / -17.99% |
| 2022-Q31/3 |
WinTARA / S&P 1.02% / -4.88% |
LoseTARA / S&P TARA unavailable / 13.47% |
LoseTARA / S&P TARA unavailable / -1.41% |
| 2022-Q20/3 |
LoseTARA / S&P -42.66% / -16.10% |
LoseTARA / S&P TARA unavailable / 13.71% |
LoseTARA / S&P TARA unavailable / 11.04% |
| 2022-Q10/3 |
LoseTARA / S&P -24.30% / -4.60% |
LoseTARA / S&P TARA unavailable / 15.97% |
LoseTARA / S&P TARA unavailable / 42.23% |
| 2021-Q40/3 |
LoseTARA / S&P -2.46% / 11.03% |
LoseTARA / S&P TARA unavailable / 15.00% |
LoseTARA / S&P TARA unavailable / 96.40% |
| 2021-Q30/3 |
LoseTARA / S&P -28.95% / 0.58% |
LoseTARA / S&P TARA unavailable / 10.77% |
LoseTARA / S&P TARA unavailable / 69.42% |
| 2021-Q20/3 |
LoseTARA / S&P -38.12% / 8.55% |
LoseTARA / S&P TARA unavailable / 6.58% |
LoseTARA / S&P TARA unavailable / 51.81% |
| 2021-Q10/3 |
LoseTARA / S&P -34.99% / 6.17% |
LoseTARA / S&P TARA unavailable / -1.06% |
LoseTARA / S&P TARA unavailable / 7.39% |
| 2020-Q41/3 |
WinTARA / S&P 43.85% / 12.15% |
LoseTARA / S&P TARA unavailable / -3.72% |
LoseTARA / S&P TARA unavailable / -33.42% |
| 2020-Q30/3 |
LoseTARA / S&P -42.60% / 8.93% |
LoseTARA / S&P TARA unavailable / -2.04% |
LoseTARA / S&P TARA unavailable / -27.10% |
| 2020-Q21/3 |
WinTARA / S&P 27.48% / 20.54% |
LoseTARA / S&P TARA unavailable / -0.46% |
LoseTARA / S&P TARA unavailable / -27.11% |
| 2020-Q11/3 |
WinTARA / S&P 40.24% / -19.60% |
LoseTARA / S&P TARA unavailable / 3.47% |
LoseTARA / S&P TARA unavailable / -14.75% |
| 2019-Q41/3 |
WinTARA / S&P 57.69% / 9.07% |
LoseTARA / S&P TARA unavailable / 5.36% |
LoseTARA / S&P TARA unavailable / 2.99% |
| 2019-Q30/3 |
LoseTARA / S&P -37.50% / 1.70% |
LoseTARA / S&P TARA unavailable / 5.02% |
LoseTARA / S&P TARA unavailable / 0.21% |
| 2019-Q20/3 |
LoseTARA / S&P -17.30% / 4.30% |
LoseTARA / S&P TARA unavailable / 6.64% |
LoseTARA / S&P TARA unavailable / 8.65% |
| 2019-Q10/3 |
LoseTARA / S&P -77.84% / 13.65% |
LoseTARA / S&P TARA unavailable / 8.12% |
LoseTARA / S&P TARA unavailable / 14.29% |
| 2018-Q41/3 |
WinTARA / S&P 16.41% / -13.52% |
LoseTARA / S&P TARA unavailable / 9.05% |
LoseTARA / S&P TARA unavailable / 18.23% |
| 2018-Q30/3 |
LoseTARA / S&P -20.41% / 7.71% |
LoseTARA / S&P TARA unavailable / 10.21% |
LoseTARA / S&P TARA unavailable / 19.06% |
| 2018-Q20/3 |
LoseTARA / S&P -2.00% / 3.43% |
LoseTARA / S&P TARA unavailable / 9.03% |
LoseTARA / S&P TARA unavailable / 14.46% |
| 2018-Q11/3 |
WinTARA / S&P 31.58% / -0.76% |
LoseTARA / S&P TARA unavailable / 7.68% |
LoseTARA / S&P TARA unavailable / 12.46% |
| 2017-Q40/3 |
LoseTARA / S&P -5.00% / 6.64% |
LoseTARA / S&P TARA unavailable / 7.03% |
LoseTARA / S&P TARA unavailable / 13.82% |
| 2017-Q31/3 |
WinTARA / S&P 31.15% / 4.48% |
LoseTARA / S&P TARA unavailable / 5.68% |
LoseTARA / S&P TARA unavailable / 17.57% |
| 2017-Q20/3 |
LoseTARA / S&P -12.86% / 3.09% |
LoseTARA / S&P TARA unavailable / 4.83% |
LoseTARA / S&P TARA unavailable / 17.74% |
| 2017-Q10/3 |
LoseTARA / S&P -7.89% / 6.07% |
LoseTARA / S&P TARA unavailable / 3.67% |
LoseTARA / S&P TARA unavailable / 13.32% |
| 2016-Q40/3 |
LoseTARA / S&P -79.64% / 3.82% |
LoseTARA / S&P TARA unavailable / 2.09% |
LoseTARA / S&P TARA unavailable / 7.05% |
| 2016-Q31/3 |
WinTARA / S&P 16.19% / 3.85% |
LoseTARA / S&P TARA unavailable / 0.20% |
LoseTARA / S&P TARA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TARA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 27.88% | 20.78% |
| Annualized return | 27.88% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | TARA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -51.28% | 83.14% |
| Annualized return | -13.40% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | TARA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.86% | 319.30% |
| Annualized return | -36.08% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |